<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02380534</url>
  </required_header>
  <id_info>
    <org_study_id>P-20140023880</org_study_id>
    <nct_id>NCT02380534</nct_id>
  </id_info>
  <brief_title>Use of Apheretic Technologies in Cardiovascular Disease</brief_title>
  <official_title>Use of H.E.L.P. Apheresis in Patients With High Cardiovascular Disease Lp(a)-Related</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effects of H.E.L.P. apheresis on lipid profile, Lp(a) level, and some
      inflammatory adypocytokines in patients with high cardiovascular risk.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lp(a) reduction</measure>
    <time_frame>1 year</time_frame>
    <description>We will evaluate the efficacy of apheretic technique through the reduction of Lp(a) in the plasma sample expressed by mg/dL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory adypocytokines</measure>
    <time_frame>1 year</time_frame>
    <description>We will evaluate the efficacy of apheretic technique through the improvement of inflammatory adypocytokines in the plasma sample.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lipid profile</measure>
    <time_frame>1 year</time_frame>
    <description>We will evaluate the efficacy of apheretic technique through the reduction of total cholesterol, LDL and HDL cholesterol, and triglycerides in the plasma sample expressed by mg/dL.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>active procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High cardiovascular risk patients will undergo H.E.L.P. apheresis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>H.E.L.P. apheresis</intervention_name>
    <description>High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.</description>
    <arm_group_label>active procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  high Lp(a) not responsive to diet and pharmacological treatment

        Exclusion Criteria:

          -  heart failure

          -  hepatic failure

          -  renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giuseppe Derosa, MD, PhD</last_name>
    <phone>+39 0382502614</phone>
    <email>giuseppe.derosa@unipv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Maffioli, MD</last_name>
    <phone>+39 0382502192</phone>
    <email>pamelamaffioli@hotmail.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Maffioli, MD</last_name>
      <phone>+39 0382 502192</phone>
      <email>pamelamaffioli@hotmail.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2015</study_first_submitted>
  <study_first_submitted_qc>February 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>February 27, 2015</last_update_submitted>
  <last_update_submitted_qc>February 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pavia</investigator_affiliation>
    <investigator_full_name>Giuseppe Derosa</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>High level of Lp(a)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

